Systemic amiloride inhibits experimentally induced neovascularization.
Amiloride is an inhibitor of urokinase-type plasminogen activator, and might therefore have an inhibitory effect on neovascularization. Neovascularization was induced in rabbit corneas via local implantation of prostaglandin E1 pellets prepared in a slow-release polymer. Animals received daily intraperitoneal injections of 30 mg of amiloride, or an equivalent volume of saline solution for 5 days; both were well tolerated without severe untoward effect. Neovascular response, as documented by corneal photographs, was evaluated after 5 days of injections. The area of induced corneal neovascularization was decreased by 55% in animals receiving amiloride when compared with controls. Thus, amiloride and similar compounds may prove useful in the study and management of neovascularization.
Avery
R L
RL
Wilmer Ophthalmological Institute, Johns Hopkins Hospital, Baltimore, MD 21205.
Connor
T B
TB
Farazdaghi
M
M
D000527:Alprostadil; D000584:Amiloride / Q000494:pharmacology*; D000818:Animals; D003315:Cornea / Q000098:blood supply / Q000187:drug effects*; D004195:Disease Models, Animal; D009389:Neovascularization, Pathologic; D010781:Photography; D011817:Rabbits
D000584:Amiloride; D000527:Alprostadil